Abiomed (ABMD) Tops Q3 EPS by 42c, Offers FY Guidance

Abiomed (NASDAQ: ABMD) reported Q3 EPS of $1.51, $0.42 better than the analyst estimate of $1.09. Revenue for the quarter came in at $221.6 million versus the consensus estimate of $226.99 million.

GUIDANCE:

Abiomed sees FY2020 revenue of $846-877 million vs $885.4 million expected)

As previously announced in January, the company revised its 2020 revenue guidance to be in the range of $846 million to $877 million, an increase of 10% to 14%, respectively. The company maintains its fiscal year 2020 guidance for GAAP operating margin within the range of 28% to 30%

For earnings history and earnings-related data on Abiomed (ABMD) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Palo Alto Networks (PANW) PT Raised to $400 at TD Cowen